BlossomHill director granted 23,904 stock options
BlossomHill Therapeutics, Inc. (BLSM) reported that director Carl L. Gordon received a grant of 23,904 Director Stock Options on August 6, 2026.
Rhea-AI Filing Summary
BlossomHill Therapeutics, Inc. (BLSM) reported that director Carl L. Gordon received a grant of 23,904 Director Stock Options on August 6, 2026. The options have an exercise price of $16.00 per share and expire on August 5, 2036. According to the vesting terms, 1/36 of the shares vest in equal monthly installments over three years following August 6, 2026. A footnote states that, under an agreement with OrbiMed Advisors LLC, Gordon is obligated to transfer any securities or economic benefits from these options to OrbiMed Advisors LLC, which will ensure they are provided to OrbiMed Private Investments VIII, LP.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 23,904 shares
Grant/Award
1 txn
Insider
GORDON CARL L
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Director Stock Option (Right to Buy) F1, F2 | 23,904 | $0.00 | $0.00 |
Holdings After Transaction:
Director Stock Option (Right to Buy) — 23,904 contracts (Direct)
Footnotes (2)
- F1. 1/36th of the shares subject to the option shall vest in equal monthly installments over a three year period following August 6, 2026.
- F2. Pursuant to an agreement with OrbiMed Advisors LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof to OrbiMed Advisors LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VIII, LP.
Key Figures
Director Stock Options Granted: 23,904 options
Exercise price: $16.00 per share
Underlying Common Stock: 23,904 shares
+3 more
6 metrics
Director Stock Options Granted
23,904 options
Grant of Director Stock Option (Right to Buy) on August 6, 2026
Exercise price
$16.00 per share
Conversion or exercise price of Director Stock Option
Underlying Common Stock
23,904 shares
Shares of Common Stock underlying the Director Stock Option
Expiration date
August 5, 2036
Expiration date of the Director Stock Option
Post-transaction option holdings
23,904 options
Total Director Stock Options held following the reported transaction
Vesting schedule
1/36 monthly over 3 years
Vesting over three-year period following August 6, 2026
Key Terms
Director Stock Option, exercise price, vesting, economic benefit, +1 more
5 terms
Director Stock Option financial
"Director Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: "16.0000""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"1/36th of the shares subject to the option shall vest"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
economic benefit financial
"transfer any securities issued or the economic benefit thereof"
Common Stock financial
"underlying_security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
What transaction did BLSM director Carl L. Gordon report on this Form 4?
Carl L. Gordon reported a grant of 23,904 Director Stock Options for BlossomHill Therapeutics, Inc. (BLSM) on August 6, 2026, representing a compensation-related acquisition rather than an open-market purchase or sale.
What is the exercise price and term of the new BLSM stock options?
The Director Stock Options granted to Carl L. Gordon have an exercise price of $16.00 per share and an expiration date of August 5, 2036, giving a 10-year term from the grant date.
How do the BLSM options granted to Carl L. Gordon vest?
The options vest over three years: 1/36 of the shares vest in equal monthly installments over a three-year period following August 6, 2026, as disclosed in the vesting footnote.
Who ultimately receives the economic benefit of Carl L. Gordon’s BLSM options?
A footnote states that, under an agreement with OrbiMed Advisors LLC, Carl L. Gordon must transfer any securities or economic benefit from these options to OrbiMed Advisors LLC, which will ensure they are provided to OrbiMed Private Investments VIII, LP.
How many BLSM options does Carl L. Gordon hold after this grant?
After this grant, Carl L. Gordon is reported as holding 23,904 Director Stock Options of BlossomHill Therapeutics, Inc., corresponding to 23,904 underlying shares of Common Stock subject to the option.
AI-generated analysis. How Rhea-AI works. Not financial advice.
